mitoxantrone has been researched along with Neoplasm Metastasis in 143 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel." | 9.22 | Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. ( de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S, 2016) |
| "The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)." | 9.11 | A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005) |
| "Doxetaxel (DCT) and mitoxantrone (MX) are highly active and potentially synergistic agents in the treatment of metastatic breast cancer (MBC)." | 9.10 | A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer. ( Breidenbach, M; König, E; Kurbacher, C; Mallmann, P; Schwonzen, M, 2002) |
| "The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial." | 9.10 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003) |
| "Early phase II evaluation of intravenous bolus mitoxantrone indicated objective response rates of 17 36% in patients with metastatic breast cancer." | 9.09 | Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. ( Fraschini, G; Holmes, FA; Hortobagyi, GN; Pusztai, L, 1999) |
| "To define the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with mitoxantrone in patients with metastatic breast cancer (MBC)." | 9.09 | Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. ( Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J, 1999) |
| "Fifty patients with stage IIIB and IV breast cancer entered a prospective study receiving combination chemotherapy consisting of mitoxantrone (8 mg/m2) on day 1, methotrexate (30 mg/m2) on day 1, vincristine (1 mg/m2) on day 2, and carboplatine (250 mg/m2) on day 2 (MIMOC), plus cyclical hormonotherapy with tamoxifen (20 mg daily, days 1-10) and megestrol acetate (160 mg daily, days 11-21)." | 9.09 | First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer. ( Agelaki, S; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kalbakis, K; Koukourakis, M; Samonis, G; Sanidas, E; Tsiftsis, D; Vlachonicolis, J, 1999) |
| "Paclitaxel and mitoxantrone are highly active agents in the treatment of advanced breast cancer (ABC)." | 9.09 | Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. ( Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L, 1999) |
| "This study evaluated mitoxantrone and paclitaxel combination chemotherapy in the treatment of patients with metastatic breast cancer." | 9.09 | Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer. ( Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W, 2001) |
| "Mitoxantrone (MTZ) and vinorelbine (VNR) have shown a good efficacy in advanced breast cancer." | 9.08 | Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study. ( Comella, G; Comella, P; Cremone, L; Della Volpe, N; Frasci, G; Imbriani, A; Persico, G; Salzano, F, 1995) |
| "Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s." | 9.08 | Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996) |
| "From January 1992 to July 1993, 28 patients with metastatic breast cancer were entered in a phase II trial to assess the activity and toxicity of the combination of mitoxantrone, 5-fluoruracil, and leucovorin." | 9.08 | Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. ( Anastasi, P; Basurto, C; Colozza, M; De Angelis, V; Giansanti, M; Gori, S; Ludovini, V; Mosconi, AM; Tonato, M, 1996) |
| "To assess efficacy and toxicity of less toxic analogs for advanced breast cancer in elderly women, we performed a phase II study using the combination mitoxantrone (MTZ)-vinorelbine (VNR)." | 9.08 | [A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women]. ( Bugat, R; Caunes, N; Chevreau, C; Gladieff, L; Houyau, P; Martinez, M; Mihura, J; Roché, H, 1996) |
| "Forty chemotherapy naive patients with metastatic or locally advanced breast cancer were treated in a randomized trial comparing mitozantrone 14 mg/m2 with epirubicin 75 mg/m2 given intravenously at 3-weekly intervals." | 9.08 | Comparison of mitozantrone and epirubicin in advanced breast cancer. ( Chambers, EJ; Cook, AM; Rees, GJ, 1996) |
| "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is a highly active single agent in the treatment of breast cancer." | 9.08 | Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer. ( Greco, FA; Hainsworth, JD, 1997) |
| "In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients with advanced breast cancer pretreated with anthracyclines." | 9.08 | Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997) |
| "In a phase II study, we treated 35 women with metastatic breast cancer with the following regimen: mitoxantrone 12 mg/m2 i." | 9.07 | The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer. ( Hainsworth, JD, 1993) |
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 9.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "A phase II study to test the toxicity and the efficacy of a weekly combination of Mitoxantrone, 5-Fluorouracil and L-Leucovorin (MFL) was carried out in 43 patients with metastatic breast cancer." | 9.07 | Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. ( Campora, E; Gardin, G; Giudici, S; Lanfranco, C; Merlini, L; Miglietta, L; Naso, C; Repetto, L; Testore, F; Venturino, A, 1994) |
| "Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle." | 9.07 | Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gravina, A; Gridelli, C; Pagliarulo, C; Perrone, F, 1994) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 9.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "In a Phase I-II clinical trial, 19 ambulatory women with metastatic breast cancer were treated with a combination of mitoxantrone, 5-fluorouracil, and leucovorin (MFL)." | 9.07 | A phase I clinical trial of a combination of mitoxantrone, 5-fluorouracil, and high-dose leucovorin given on a day 1 and day 8 schedule to patients with metastatic breast cancer. ( Gomez, EG; Vogel, CL, 1994) |
| "Ninety-three evaluable patients with metastatic breast cancer previously treated with chemotherapy, received mitoxantrone as a single agent (14 mg/m2, by rapid intravenous infusion, once every 3 weeks)." | 9.07 | Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer. ( Ben-Baruch, N; Brufman, G; Haim, N; Sulkes, A, 1993) |
| "Fifty-five women with metastatic breast cancer were treated with carboplatin (CBDCA), 55 mg/m2 i." | 9.07 | Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer. ( Gonzalez, FG; Herranz, P; Hidalgo, OF; Rebollo, J; Tangco, E; Vieitez, JM, 1992) |
| "A new combination of mitoxantrone, folinic acid (leucovorin), and infusional fluorouracil (5-FU) was administered to 57 previously treated patients with metastatic breast cancer to evaluate the response rate, response duration, and toxicity of this regimen." | 9.07 | Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. ( Allison, MA; Brooks, B; Jones, SE; Mennel, RG; Paulson, RS; Rea, B; Tilmann, K; Westrick, MA, 1991) |
| "Between September 1988 and August 1990, we treated 35 women with metastatic breast cancer with a novel regimen containing mitoxantrone, fluorouracil (5-FU), and high-dose leucovorin." | 9.07 | Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. ( Andrews, MB; Greco, FA; Hainsworth, JD; Johnson, DH, 1991) |
| "Three hundred twenty-five women with metastatic adenocarcinoma of the breast who had failed one prior chemotherapeutic regimen for advanced disease were randomized to receive 14 mg/m2 of mitoxantrone or 75 mg/m2 of doxorubicin intravenously (IV) every 3 weeks." | 9.06 | Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. ( Allegra, JC; Bryan, S; Cartwright, K; Dukart, G; Henderson, IC; Henry, D; Wolff, S; Woodcock, T, 1989) |
| "Twenty-seven women with metastatic breast cancer were treated with mitoxantrone as a single agent, with the use of an intensive dose-escalating schedule." | 9.06 | Intensive single-agent mitoxantrone for metastatic breast cancer. ( Bhardwaj, S; Holland, JF; Jones, RB; Paciucci, PA; Shpall, EJ; Strashun, A; Wilfinger, CL, 1988) |
| "Ninety patients with breast cancer refractory to cyclophosphamide/fluorouracil/methotrexate (CMF) have been randomized in their treatment, receiving either doxorubicin or mitoxantrone." | 9.06 | A comparison of mitoxantrone and doxorubicin in breast cancer. ( Gochnour, D; Hoth, D; Neidhart, JA; Roach, R; Young, D, 1986) |
| "Fifty-five patients with newly diagnosed, estrogen receptor negative, metastatic breast cancer were entered in a trial of mitoxantrone, 10 mg/m2 intravenous (IV), cyclophosphamide, 500 mg/m2 IV, and 5-fluorouracil, 1000 mg/m2 IV, which were given on day 1 of a 21-day treatment interval." | 9.05 | Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Yap, HY, 1984) |
| "Trials establishing the safety and efficacy of single-agent vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) as first- and second-line chemotherapy for metastatic breast cancer led to testing of the combination of vinorelbine and mitoxantrone." | 8.79 | Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review. ( Vogel, CL, 1995) |
| "Most breast cancers (BCs) express estrogen receptor α (ERα) and are treated with the endocrine therapy (ET) drugs 4OH-tamoxifen (Tam) and fulvestrant (ICI 182,780; ICI)." | 7.88 | In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells. ( Acconcia, F; Bianchi, F; Busonero, C; Leone, S, 2018) |
| "We treated 39 women with newly diagnosed stage IV breast cancer with a new regimen of mitoxantrone 18 mg/m2 on days 1, 29, 57, vincristine 1." | 7.68 | Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer. ( Bitran, JD; Huffman, S; Mick, R; Myers, SE; Williams, SF, 1993) |
| "Mitoxantrone (DHAD), an anthracenedione with antineoplastic properties similar to doxorubicin, was tested for therapeutic efficacy and for immunomodulating action on lymphocyte subsets in 16 metastatic breast cancer patients, 12 of whom had been previously treated with chemotherapy." | 7.68 | Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response. ( Archili, C; Barni, S; Cattaneo, G; Crispino, S; Lissoni, P; Paolorossi, F; Rescaldani, R; Tancini, G, 1991) |
| "Eleven patients (pts) with advanced refractory breast carcinoma were treated with combination chemotherapy (Planovin) including mitoxantrone 10 mg/m2 on day 1, cisplatin 60 mg/m2 on days 1-2, methotrexate 200 mg/m2 on day 15, vincristine 2 mg on day 15, leucovorin 15 mg/m2 on days 15-16 every 3 weeks." | 7.68 | Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer. ( Gardin, G; Guido, T; Miglietta, L; Pronzato, P; Queirolo, P; Repetto, L; Rosso, R, 1991) |
| "To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP)." | 7.68 | A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. ( Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J, 1990) |
| "Thirty-three patients with metastatic breast cancer received 135 cycles of chemotherapy consisting of mitoxantrone, methotrexate and chlorambucil." | 7.68 | Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity. ( Burghouts, JT, 1990) |
| "A total of 134 patients with advanced breast cancer and no prior chemotherapy for advanced disease were treated with mitoxantrone, 14 mg/m2 intravenously every 3 weeks." | 7.67 | Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study. ( Coleman, RE; Cornbleet, MA; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, RD; Smith, IE; Smyth, JF; Stuart-Harris, RC; van Oosterom, AT, 1984) |
| "A total of 56 heavily pretreated patients with advanced breast cancer were treated with the combination mitomycin and mitoxantrone." | 7.67 | Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. ( Bishop, JF; Burns, I; Coates, A; Hillcoat, BL; Jeal, PN; Raghavan, D; Tattersall, MN; Woods, R, 1987) |
| "Fifty-two patients with hormonally unresponsive or estrogen receptor negative metastatic breast cancer who had not received prior chemotherapy received mitoxantrone 10 mg/m2, cyclophosphamide 500 mg/m2, and 5-fluorouracil 1000 mg/m2 (MCF) by short intravenous infusion every 21 days." | 7.67 | Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Hug, V; Yap, HY, 1987) |
| "A total of 39 women with metastatic breast cancer entered a pilot phase II study of the vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy." | 7.67 | Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study. ( Belpomme, D; Cour, V; George, C; Gisselbrecht, C; Heritier, F; Le Rol, A; Maral, J; Marty, M; Michaud, G, 1987) |
| "Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer." | 7.67 | Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer. ( Bezwoda, WR; Dansey, RD; Hesdorffer, CS, 1987) |
| "A phase II study of mitoxantrone in cases of advanced breast cancer was conducted by a cooperative study group involving 7 institutions." | 7.67 | [Phase II study of mitoxantrone in advanced breast cancer]. ( Hoshino, A; Kubo, K; Nomura, Y; Ogawa, M; Ota, K; Taguchi, T; Tominaga, T; Yoshida, M, 1986) |
| "Results of first-line mitoxantrone chemotherapy for advanced breast cancer are presented." | 7.67 | First-line mitoxantrone chemotherapy for advanced breast cancer. ( Paterson, AH; Wilson, KS, 1986) |
| "The new anthracendione mitoxantrone, an anthraquinone derivate with structural similarities to doxorubicin (adriamycin) is active in the treatment of patients with metastatic breast cancer." | 7.67 | [Mitoxantrone in a combination regimen in advanced breast cancer]. ( Hausmaninger, H, 1985) |
| "124 patients with metastatic breast cancer were entered into this phase II trial of mitoxantrone (DHAD)." | 7.66 | Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group. ( Fabian, C; Jones, SE; Knight, WA; Neidhart, JA; Tranum, BL; Von Hoff, DD, 1983) |
| "Treatment with cabazitaxel was prognostic for survival ≥2 years." | 6.78 | Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. ( Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B, 2013) |
| "Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy." | 6.70 | Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001) |
| " No apparent dose-response relationship was observed in our study." | 6.69 | Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. ( Buzdar, AU; Cristofanilli, M; Esparza, L; Holmes, FA; Hortobagyi, GN; Neidhart, JA; Valero, V, 1999) |
| "Advanced breast cancer remains a major clinical problem." | 6.68 | A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients. ( Leonardi, V; Meli, M; Palmeri, S; Peralta, S; Rausa, L; Rini, GB; Russo, A, 1995) |
| "Of the 21 patients who had carcinoid tumours, 11 were previously untreated and two achieved a response (18%, 95% CI = 2-52%)." | 6.68 | Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. ( Lacave, AJ; Lips, CJ; Neijt, JP; Sahmoud, T; Splinter, TA; Taal, BG; Veenhof, CH, 1995) |
| "24 patients with advanced breast cancer entered the study: 16 aged 65-70 yrs, 4 patients 70-75 yrs, and 4 > 75 yrs." | 6.68 | Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients. ( Caroti, C; Gallo, L; Mammoliti, S; Merlini, L, 1996) |
| "Sixty-one metastatic breast cancer patients with a mean age of 40 years were included." | 6.68 | Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. ( Bremond, D; Delain, M; Devaux, Y; Extra, JM; Gisselbrecht, C; Guillevin, L; Herbrecht, R; Janvier, M; Lepage, E; Lotz, JP; Maraninchi, D; Peny, AM, 1996) |
| "All patients had advanced metastatic breast cancer and have been extensively pretreated with chemotherapy (28 patients), radiotherapy (13 patients), and hormonotherapy (24 patients)." | 6.68 | Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. ( Panagos, GE, 1997) |
| "Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue." | 6.67 | Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993) |
| "182 patients with metastatic breast cancer were randomized to V (mg/m2 i." | 6.66 | Vindesine-mitoxantrone (VM) versus vindesine-4'-epidoxorubicin (VE) in metastatic breast cancer: a prospective randomized trial. ( Hausmaninger, H; Lehnert, M, 1988) |
| "Mitoxantrone appears to be an effective and well-tolerated agent for breast cancer." | 6.65 | A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer. ( Gochnour, D; Neidhart, JA; Roach, RW; Steinberg, JA; Young, D, 1984) |
| "All 11 patients had liver and/or lung metastases." | 5.28 | Anthracycline-carboplatin combination in metastatic breast cancer. ( Jungi, WF; Senn, HJ; Thürlimann, B, 1990) |
| "Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel." | 5.22 | Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. ( de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S, 2016) |
| "To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed." | 5.13 | The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. ( Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E, 2008) |
| " To evaluate the efficacy and toxicity of biweekly docetaxel and mitoxantrone in patients with advanced breast cancer, the regimen consisting of docetaxel (60 mg/m), and mitoxantrone (8 mg/m) was administered intravenously to 59 patients every 2 weeks." | 5.13 | Biweekly docetaxel-containing chemotherapy may be the optimal schedule. ( Cai, Y; Hong, X; Hu, X; Li, J; Ou, Z; Shen, Z; Wang, Z; Yang, X; Zhao, X, 2008) |
| "The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)." | 5.11 | A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005) |
| "Doxetaxel (DCT) and mitoxantrone (MX) are highly active and potentially synergistic agents in the treatment of metastatic breast cancer (MBC)." | 5.10 | A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer. ( Breidenbach, M; König, E; Kurbacher, C; Mallmann, P; Schwonzen, M, 2002) |
| "The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial." | 5.10 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003) |
| "Early phase II evaluation of intravenous bolus mitoxantrone indicated objective response rates of 17 36% in patients with metastatic breast cancer." | 5.09 | Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. ( Fraschini, G; Holmes, FA; Hortobagyi, GN; Pusztai, L, 1999) |
| "To define the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with mitoxantrone in patients with metastatic breast cancer (MBC)." | 5.09 | Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. ( Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J, 1999) |
| "Fifty patients with stage IIIB and IV breast cancer entered a prospective study receiving combination chemotherapy consisting of mitoxantrone (8 mg/m2) on day 1, methotrexate (30 mg/m2) on day 1, vincristine (1 mg/m2) on day 2, and carboplatine (250 mg/m2) on day 2 (MIMOC), plus cyclical hormonotherapy with tamoxifen (20 mg daily, days 1-10) and megestrol acetate (160 mg daily, days 11-21)." | 5.09 | First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer. ( Agelaki, S; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kalbakis, K; Koukourakis, M; Samonis, G; Sanidas, E; Tsiftsis, D; Vlachonicolis, J, 1999) |
| "Paclitaxel and mitoxantrone are highly active agents in the treatment of advanced breast cancer (ABC)." | 5.09 | Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. ( Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L, 1999) |
| "This study evaluated mitoxantrone and paclitaxel combination chemotherapy in the treatment of patients with metastatic breast cancer." | 5.09 | Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer. ( Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W, 2001) |
| "Mitoxantrone (MTZ) and vinorelbine (VNR) have shown a good efficacy in advanced breast cancer." | 5.08 | Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study. ( Comella, G; Comella, P; Cremone, L; Della Volpe, N; Frasci, G; Imbriani, A; Persico, G; Salzano, F, 1995) |
| "A phase II trial was performed to assess the efficacy and toxicity of the combination mitoxantrone (MXN) and vinorelbine (VNR) as first-line chemotherapy for metastatic breast cancer." | 5.08 | [Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma]. ( Ferrero, JM; François, E; Frenay, M; Hoch, M; Namer, M; Pivot, X; Teissier, E; Wendling, JL, 1995) |
| "Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s." | 5.08 | Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996) |
| "From January 1992 to July 1993, 28 patients with metastatic breast cancer were entered in a phase II trial to assess the activity and toxicity of the combination of mitoxantrone, 5-fluoruracil, and leucovorin." | 5.08 | Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. ( Anastasi, P; Basurto, C; Colozza, M; De Angelis, V; Giansanti, M; Gori, S; Ludovini, V; Mosconi, AM; Tonato, M, 1996) |
| "To assess efficacy and toxicity of less toxic analogs for advanced breast cancer in elderly women, we performed a phase II study using the combination mitoxantrone (MTZ)-vinorelbine (VNR)." | 5.08 | [A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women]. ( Bugat, R; Caunes, N; Chevreau, C; Gladieff, L; Houyau, P; Martinez, M; Mihura, J; Roché, H, 1996) |
| "Forty chemotherapy naive patients with metastatic or locally advanced breast cancer were treated in a randomized trial comparing mitozantrone 14 mg/m2 with epirubicin 75 mg/m2 given intravenously at 3-weekly intervals." | 5.08 | Comparison of mitozantrone and epirubicin in advanced breast cancer. ( Chambers, EJ; Cook, AM; Rees, GJ, 1996) |
| "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is a highly active single agent in the treatment of breast cancer." | 5.08 | Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer. ( Greco, FA; Hainsworth, JD, 1997) |
| "In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients with advanced breast cancer pretreated with anthracyclines." | 5.08 | Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997) |
| "In a phase II study, we treated 35 women with metastatic breast cancer with the following regimen: mitoxantrone 12 mg/m2 i." | 5.07 | The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer. ( Hainsworth, JD, 1993) |
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 5.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "A phase II study to test the toxicity and the efficacy of a weekly combination of Mitoxantrone, 5-Fluorouracil and L-Leucovorin (MFL) was carried out in 43 patients with metastatic breast cancer." | 5.07 | Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. ( Campora, E; Gardin, G; Giudici, S; Lanfranco, C; Merlini, L; Miglietta, L; Naso, C; Repetto, L; Testore, F; Venturino, A, 1994) |
| "Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle." | 5.07 | Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gravina, A; Gridelli, C; Pagliarulo, C; Perrone, F, 1994) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 5.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "In a Phase I-II clinical trial, 19 ambulatory women with metastatic breast cancer were treated with a combination of mitoxantrone, 5-fluorouracil, and leucovorin (MFL)." | 5.07 | A phase I clinical trial of a combination of mitoxantrone, 5-fluorouracil, and high-dose leucovorin given on a day 1 and day 8 schedule to patients with metastatic breast cancer. ( Gomez, EG; Vogel, CL, 1994) |
| "Ninety-three evaluable patients with metastatic breast cancer previously treated with chemotherapy, received mitoxantrone as a single agent (14 mg/m2, by rapid intravenous infusion, once every 3 weeks)." | 5.07 | Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer. ( Ben-Baruch, N; Brufman, G; Haim, N; Sulkes, A, 1993) |
| "Fifty-five women with metastatic breast cancer were treated with carboplatin (CBDCA), 55 mg/m2 i." | 5.07 | Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer. ( Gonzalez, FG; Herranz, P; Hidalgo, OF; Rebollo, J; Tangco, E; Vieitez, JM, 1992) |
| "A new combination of mitoxantrone, folinic acid (leucovorin), and infusional fluorouracil (5-FU) was administered to 57 previously treated patients with metastatic breast cancer to evaluate the response rate, response duration, and toxicity of this regimen." | 5.07 | Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. ( Allison, MA; Brooks, B; Jones, SE; Mennel, RG; Paulson, RS; Rea, B; Tilmann, K; Westrick, MA, 1991) |
| "Between September 1988 and August 1990, we treated 35 women with metastatic breast cancer with a novel regimen containing mitoxantrone, fluorouracil (5-FU), and high-dose leucovorin." | 5.07 | Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. ( Andrews, MB; Greco, FA; Hainsworth, JD; Johnson, DH, 1991) |
| "Three hundred twenty-five women with metastatic adenocarcinoma of the breast who had failed one prior chemotherapeutic regimen for advanced disease were randomized to receive 14 mg/m2 of mitoxantrone or 75 mg/m2 of doxorubicin intravenously (IV) every 3 weeks." | 5.06 | Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. ( Allegra, JC; Bryan, S; Cartwright, K; Dukart, G; Henderson, IC; Henry, D; Wolff, S; Woodcock, T, 1989) |
| "Twenty-seven women with metastatic breast cancer were treated with mitoxantrone as a single agent, with the use of an intensive dose-escalating schedule." | 5.06 | Intensive single-agent mitoxantrone for metastatic breast cancer. ( Bhardwaj, S; Holland, JF; Jones, RB; Paciucci, PA; Shpall, EJ; Strashun, A; Wilfinger, CL, 1988) |
| "Ninety patients with breast cancer refractory to cyclophosphamide/fluorouracil/methotrexate (CMF) have been randomized in their treatment, receiving either doxorubicin or mitoxantrone." | 5.06 | A comparison of mitoxantrone and doxorubicin in breast cancer. ( Gochnour, D; Hoth, D; Neidhart, JA; Roach, R; Young, D, 1986) |
| "Fifty-five patients with newly diagnosed, estrogen receptor negative, metastatic breast cancer were entered in a trial of mitoxantrone, 10 mg/m2 intravenous (IV), cyclophosphamide, 500 mg/m2 IV, and 5-fluorouracil, 1000 mg/m2 IV, which were given on day 1 of a 21-day treatment interval." | 5.05 | Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Yap, HY, 1984) |
| "Trials establishing the safety and efficacy of single-agent vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) as first- and second-line chemotherapy for metastatic breast cancer led to testing of the combination of vinorelbine and mitoxantrone." | 4.79 | Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review. ( Vogel, CL, 1995) |
| "Most breast cancers (BCs) express estrogen receptor α (ERα) and are treated with the endocrine therapy (ET) drugs 4OH-tamoxifen (Tam) and fulvestrant (ICI 182,780; ICI)." | 3.88 | In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells. ( Acconcia, F; Bianchi, F; Busonero, C; Leone, S, 2018) |
| "Nineteen patients with metastatic breast cancer and six patients with refractory non-Hodgkin's lymphoma were initially treated with etoposide (VP-16) (2 gm/m2) and granulocyte-colony stimulating factor (G-CSF)." | 3.69 | Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. ( Blume, KG; Chao, NJ; Hoyle, CF; Kusnierz-Glaz, CR; Long, GD; Negrin, RS; Schriber, JR, 1995) |
| "Fifty-three metastatic breast cancer patients were treated with a four-drug program of high-dose chemotherapy including cyclophosphamide (6 g/m2), thiotepa (500 mg/m2), carboplatin (800-1,600 mg/m2) and mitoxantrone (20-60 mg/m2) with autologous peripheral blood progenitor cell support followed by filgrastim." | 3.69 | [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer]. ( Alonso, JL; Ayala, F; Casado, A; Díaz-Rubio, E; Llorente, L; López Martín, JA; Martín, M; Nieto, Y; Pérez Calvo, J; Pérez López, C; Rodríguez Lescure, A; Villegas, A, 1997) |
| "We treated 39 women with newly diagnosed stage IV breast cancer with a new regimen of mitoxantrone 18 mg/m2 on days 1, 29, 57, vincristine 1." | 3.68 | Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer. ( Bitran, JD; Huffman, S; Mick, R; Myers, SE; Williams, SF, 1993) |
| "Mitoxantrone (DHAD), an anthracenedione with antineoplastic properties similar to doxorubicin, was tested for therapeutic efficacy and for immunomodulating action on lymphocyte subsets in 16 metastatic breast cancer patients, 12 of whom had been previously treated with chemotherapy." | 3.68 | Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response. ( Archili, C; Barni, S; Cattaneo, G; Crispino, S; Lissoni, P; Paolorossi, F; Rescaldani, R; Tancini, G, 1991) |
| "Eleven patients (pts) with advanced refractory breast carcinoma were treated with combination chemotherapy (Planovin) including mitoxantrone 10 mg/m2 on day 1, cisplatin 60 mg/m2 on days 1-2, methotrexate 200 mg/m2 on day 15, vincristine 2 mg on day 15, leucovorin 15 mg/m2 on days 15-16 every 3 weeks." | 3.68 | Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer. ( Gardin, G; Guido, T; Miglietta, L; Pronzato, P; Queirolo, P; Repetto, L; Rosso, R, 1991) |
| "To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP)." | 3.68 | A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. ( Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J, 1990) |
| "Thirty-three patients with metastatic breast cancer received 135 cycles of chemotherapy consisting of mitoxantrone, methotrexate and chlorambucil." | 3.68 | Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity. ( Burghouts, JT, 1990) |
| "A total of 134 patients with advanced breast cancer and no prior chemotherapy for advanced disease were treated with mitoxantrone, 14 mg/m2 intravenously every 3 weeks." | 3.67 | Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study. ( Coleman, RE; Cornbleet, MA; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, RD; Smith, IE; Smyth, JF; Stuart-Harris, RC; van Oosterom, AT, 1984) |
| "A total of 56 heavily pretreated patients with advanced breast cancer were treated with the combination mitomycin and mitoxantrone." | 3.67 | Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. ( Bishop, JF; Burns, I; Coates, A; Hillcoat, BL; Jeal, PN; Raghavan, D; Tattersall, MN; Woods, R, 1987) |
| "Fifty-two patients with hormonally unresponsive or estrogen receptor negative metastatic breast cancer who had not received prior chemotherapy received mitoxantrone 10 mg/m2, cyclophosphamide 500 mg/m2, and 5-fluorouracil 1000 mg/m2 (MCF) by short intravenous infusion every 21 days." | 3.67 | Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Hug, V; Yap, HY, 1987) |
| "A total of 39 women with metastatic breast cancer entered a pilot phase II study of the vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy." | 3.67 | Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study. ( Belpomme, D; Cour, V; George, C; Gisselbrecht, C; Heritier, F; Le Rol, A; Maral, J; Marty, M; Michaud, G, 1987) |
| "Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer." | 3.67 | Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer. ( Bezwoda, WR; Dansey, RD; Hesdorffer, CS, 1987) |
| "A phase II study of mitoxantrone in cases of advanced breast cancer was conducted by a cooperative study group involving 7 institutions." | 3.67 | [Phase II study of mitoxantrone in advanced breast cancer]. ( Hoshino, A; Kubo, K; Nomura, Y; Ogawa, M; Ota, K; Taguchi, T; Tominaga, T; Yoshida, M, 1986) |
| "Results of first-line mitoxantrone chemotherapy for advanced breast cancer are presented." | 3.67 | First-line mitoxantrone chemotherapy for advanced breast cancer. ( Paterson, AH; Wilson, KS, 1986) |
| "The new anthracendione mitoxantrone, an anthraquinone derivate with structural similarities to doxorubicin (adriamycin) is active in the treatment of patients with metastatic breast cancer." | 3.67 | [Mitoxantrone in a combination regimen in advanced breast cancer]. ( Hausmaninger, H, 1985) |
| "124 patients with metastatic breast cancer were entered into this phase II trial of mitoxantrone (DHAD)." | 3.66 | Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group. ( Fabian, C; Jones, SE; Knight, WA; Neidhart, JA; Tranum, BL; Von Hoff, DD, 1983) |
| "Treatment with cabazitaxel was prognostic for survival ≥2 years." | 2.78 | Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. ( Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B, 2013) |
| "These results suggest that the combination of ixabepilone and mitoxantrone is both feasible and active in castration-resistant prostate cancer and requires dosing with pegfilgrastim." | 2.76 | Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. ( Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2011) |
| "Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy." | 2.70 | Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001) |
| " Furthermore, we evaluated the times for hematopoietic reconstitution in a group of five BC patients in the high-risk adjuvant situation who underwent HD chemotherapy and hematopoietic rescue with positive/negative selected stem cells and compared it with our own data from 10 BC patients who, after identical HD therapy, received only positively selected CD34+ cells and 14 patients who, after identical HD therapy, received autografts purged by incubation with toxic ether lipids (ET-18-OCH3)." | 2.69 | Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. ( Berdel, WE; Cassens, U; Fietz, T; Hilgenfeld, E; Hoffmann, M; Hoppe, B; Kienast, J; Knauf, WU; Koenigsmann, M; Mohr, M; Sibrowski, W; Thiel, E, 1999) |
| " No apparent dose-response relationship was observed in our study." | 2.69 | Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. ( Buzdar, AU; Cristofanilli, M; Esparza, L; Holmes, FA; Hortobagyi, GN; Neidhart, JA; Valero, V, 1999) |
| "Patients with localized prostate cancer receiving adjuvant chemotherapy had a higher initial objective response rate (95% vs 53%, P = 0." | 2.69 | Adjuvant mitozantrone chemotherapy in advanced prostate cancer. ( Halford, S; Lynch, M; Rigg, A; Roylance, R; Wang, J; Waxman, J, 2000) |
| "Advanced breast cancer remains a major clinical problem." | 2.68 | A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients. ( Leonardi, V; Meli, M; Palmeri, S; Peralta, S; Rausa, L; Rini, GB; Russo, A, 1995) |
| "Of the 21 patients who had carcinoid tumours, 11 were previously untreated and two achieved a response (18%, 95% CI = 2-52%)." | 2.68 | Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. ( Lacave, AJ; Lips, CJ; Neijt, JP; Sahmoud, T; Splinter, TA; Taal, BG; Veenhof, CH, 1995) |
| "24 patients with advanced breast cancer entered the study: 16 aged 65-70 yrs, 4 patients 70-75 yrs, and 4 > 75 yrs." | 2.68 | Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients. ( Caroti, C; Gallo, L; Mammoliti, S; Merlini, L, 1996) |
| " Dosage in subsequent cycles was adjusted according to hematologic toxicity." | 2.68 | A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. ( Carroll, PR; Ernest, ML; Fippin, LJ; Small, EJ, 1996) |
| "Sixty-one metastatic breast cancer patients with a mean age of 40 years were included." | 2.68 | Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. ( Bremond, D; Delain, M; Devaux, Y; Extra, JM; Gisselbrecht, C; Guillevin, L; Herbrecht, R; Janvier, M; Lepage, E; Lotz, JP; Maraninchi, D; Peny, AM, 1996) |
| "All patients had advanced metastatic breast cancer and have been extensively pretreated with chemotherapy (28 patients), radiotherapy (13 patients), and hormonotherapy (24 patients)." | 2.68 | Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. ( Panagos, GE, 1997) |
| "Thirty-one patients with metastatic breast cancer treated on three successive high-dose chemotherapy and autologous bone marrow transplantation trials between January 1987 and March 1992 who achieved a complete response were evaluated." | 2.67 | Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy. ( Halpern, H; Heimann, R; Mundt, AJ; Rubin, SJ; Sibley, GS; Weichselbaum, RR; Williams, S, 1994) |
| "Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue." | 2.67 | Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993) |
| "182 patients with metastatic breast cancer were randomized to V (mg/m2 i." | 2.66 | Vindesine-mitoxantrone (VM) versus vindesine-4'-epidoxorubicin (VE) in metastatic breast cancer: a prospective randomized trial. ( Hausmaninger, H; Lehnert, M, 1988) |
| "Mitoxantrone appears to be an effective and well-tolerated agent for breast cancer." | 2.65 | A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer. ( Gochnour, D; Neidhart, JA; Roach, RW; Steinberg, JA; Young, D, 1984) |
| "Abiraterone acetate has recently demonstrated a significant improvement in survival when compared to placebo in patients with docetaxel-treated mCRPC." | 2.47 | Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. ( Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R, 2011) |
| "Treatment of hormone-refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases." | 2.43 | The changing pattern of management for hormone-refractory, metastatic prostate cancer. ( Bloomfield, D; James, ND; Luscombe, C, 2006) |
| " The pharmacokinetic parameters are described adequately by a three-compartment model with a terminal half-life of 71." | 2.38 | Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. ( Chang, SP; Chen, KY; Hu, OY; Jian, JM; Law, CK, 1992) |
| "Mitoxantrone is a DNA topoisomerase II poison commonly used for the treatment of hormone-refractory prostate cancer." | 1.34 | Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer. ( Bouscary, D; Dômont, J; Goldwasser, F; Martinez, V; Mir, O, 2007) |
| "Mitoxantrone is a minimally toxic chemotherapeutic agent, which justifies its current indication in hormone-resistant advanced prostate cancer." | 1.31 | [Value of mitoxantrone in metastatic hormone-resistant prostate cancer]. ( Dunet, F; Grise, P; Hellot, MF; Khalaf, A; Moussu, J; Pfister, C, 2002) |
| "All 11 patients had liver and/or lung metastases." | 1.28 | Anthracycline-carboplatin combination in metastatic breast cancer. ( Jungi, WF; Senn, HJ; Thürlimann, B, 1990) |
| "Mitoxantrone is a promising new agent developed in an attempt to find drugs with a broad spectrum of antitumor activity and devoid of cardiotoxicity." | 1.26 | Potential cardiotoxicity with mitoxantrone. ( Blumenschein, G; Bodey, G; Schell, FC; Valdivieso, M; Yap, HY, 1982) |
| "Thirty-one patients who had metastatic breast cancer extensively pretreated with combination chemotherapy, including doxorubicin, were tested with dihydroxyanthracenedione, 3 to 4 mg/m2 body surface area daily for 5 consecutive days every 4 weeks." | 1.26 | Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Schell, FC; Valdivieso, M; Yap, HY, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (23.08) | 18.7374 |
| 1990's | 58 (40.56) | 18.2507 |
| 2000's | 28 (19.58) | 29.6817 |
| 2010's | 23 (16.08) | 24.3611 |
| 2020's | 1 (0.70) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q | 1 |
| Zhai, Y | 1 |
| Luo, W | 1 |
| Zhu, Z | 1 |
| Zhang, X | 1 |
| Xie, S | 1 |
| Hong, C | 1 |
| Wang, Y | 1 |
| Su, Y | 1 |
| Zhao, J | 1 |
| Wang, C | 1 |
| Zhou, S | 1 |
| Shang, Q | 1 |
| Ji, J | 1 |
| Luan, Y | 1 |
| Busonero, C | 1 |
| Leone, S | 1 |
| Bianchi, F | 1 |
| Acconcia, F | 1 |
| Grochtdreis, T | 1 |
| König, HH | 1 |
| Dobruschkin, A | 1 |
| von Amsberg, G | 1 |
| Dams, J | 1 |
| Hakenberg, OW | 1 |
| Perez-Gracia, JL | 2 |
| Castellano, D | 1 |
| Demkow, T | 1 |
| Ali, T | 1 |
| Caffo, O | 1 |
| Heidenreich, A | 2 |
| Schultze-Seemann, W | 1 |
| Sautois, B | 1 |
| Pavlik, I | 1 |
| Qin, A | 1 |
| Novosiadly, RD | 1 |
| Shahir, A | 1 |
| Ilaria, R | 1 |
| Nippgen, J | 1 |
| Halabi, S | 4 |
| Dutta, S | 1 |
| Tangen, CM | 1 |
| Rosenthal, M | 1 |
| Petrylak, DP | 1 |
| Thompson, IM | 1 |
| Chi, KN | 3 |
| Araujo, JC | 1 |
| Logothetis, C | 1 |
| Quinn, DI | 1 |
| Fizazi, K | 3 |
| Morris, MJ | 1 |
| Eisenberger, MA | 1 |
| George, DJ | 2 |
| De Bono, JS | 3 |
| Higano, CS | 1 |
| Tannock, IF | 3 |
| Small, EJ | 4 |
| Kelly, WK | 1 |
| Lafrenie, RM | 1 |
| Speigl, L | 1 |
| Buckner, CA | 1 |
| Pawelec, G | 1 |
| Conlon, MS | 1 |
| Shipp, C | 1 |
| Aragon-Ching, JB | 1 |
| Bahl, A | 2 |
| Oudard, S | 3 |
| Tombal, B | 1 |
| Ozgüroglu, M | 1 |
| Hansen, S | 1 |
| Kocak, I | 1 |
| Gravis, G | 1 |
| Devin, J | 1 |
| Shen, L | 1 |
| Sartor, AO | 1 |
| Harzstark, AL | 1 |
| Rosenberg, JE | 1 |
| Weinberg, VK | 1 |
| Sharib, J | 1 |
| Ryan, CJ | 1 |
| Smith, DC | 1 |
| Pagliaro, LC | 1 |
| Beer, TM | 2 |
| Liu, G | 1 |
| Armstrong, AJ | 3 |
| Sartor, O | 2 |
| de Bono, J | 2 |
| Kaplan, E | 1 |
| Lin, CY | 1 |
| Solomon, NC | 1 |
| Joly, F | 1 |
| Delva, R | 1 |
| Mourey, L | 1 |
| Sevin, E | 1 |
| Bompas, E | 1 |
| Vedrine, L | 1 |
| Ravaud, A | 1 |
| Eymard, JC | 1 |
| Tubiana-Mathieu, N | 1 |
| Linassier, C | 1 |
| Houede, N | 1 |
| Guillot, A | 1 |
| Ringensen, F | 1 |
| Cojocarasu, O | 1 |
| Valenza, B | 1 |
| Leconte, A | 1 |
| Lheureux, S | 1 |
| Clarisse, B | 1 |
| Meisel, A | 1 |
| von Felten, S | 1 |
| Vogt, DR | 1 |
| Liewen, H | 1 |
| de Wit, R | 3 |
| Stenner-Liewen, F | 1 |
| Yu, P | 1 |
| Diao, W | 1 |
| Jiang, X | 1 |
| Saad, F | 2 |
| Ruether, D | 1 |
| Ernst, S | 1 |
| North, S | 2 |
| Cheng, T | 1 |
| Perrotte, P | 1 |
| Karakiewicz, P | 1 |
| Winquist, E | 2 |
| Beardsley, EK | 1 |
| Eisenberger, M | 2 |
| DiPaola, RS | 1 |
| Chen, YH | 1 |
| Stein, M | 2 |
| Vaughn, D | 1 |
| Patrick-Miller, L | 1 |
| Carducci, M | 1 |
| Roth, B | 1 |
| White, E | 1 |
| Wilding, G | 1 |
| Eton, DT | 1 |
| Shevrin, DH | 1 |
| Beaumont, J | 1 |
| Victorson, D | 1 |
| Cella, D | 1 |
| Pinto, AC | 1 |
| Ângelo, S | 1 |
| Moreira, JN | 1 |
| Simões, S | 1 |
| Ansari, J | 1 |
| Hussain, SA | 1 |
| Alhasso, A | 1 |
| Mahmood, R | 1 |
| Ansari, A | 1 |
| Glaholm, J | 1 |
| Hotte, S | 1 |
| Eigl, B | 1 |
| Chi, K | 1 |
| Czaykowski, P | 1 |
| Wood, L | 1 |
| Pollak, M | 1 |
| Berry, S | 1 |
| Lattouf, JB | 1 |
| Mukherjee, SD | 1 |
| Gleave, M | 1 |
| Flechon, A | 1 |
| Voog, E | 1 |
| Davis, NB | 1 |
| Qi, M | 1 |
| Bandekar, R | 1 |
| Vermeulen, JT | 1 |
| Cornfeld, M | 1 |
| Hudes, GR | 1 |
| Shen, YJ | 1 |
| Bian, XJ | 1 |
| Xie, HY | 1 |
| Zhu, Y | 1 |
| Zhang, HL | 1 |
| Dai, B | 1 |
| Zhang, SL | 1 |
| Yao, XD | 1 |
| Ye, DW | 1 |
| Gilligan, T | 1 |
| Kantoff, PW | 2 |
| König, E | 1 |
| Kurbacher, C | 1 |
| Schwonzen, M | 1 |
| Breidenbach, M | 1 |
| Mallmann, P | 1 |
| Lorusso, V | 1 |
| Crucitta, E | 1 |
| Silvestris, N | 1 |
| Catino, A | 1 |
| Caporusso, L | 1 |
| Mazzei, A | 1 |
| Guida, M | 1 |
| Latorre, A | 1 |
| Sambiasi, D | 1 |
| D'Amico, C | 1 |
| Schittulli, F | 1 |
| Calabrese, P | 1 |
| De Lena, M | 1 |
| Rago, RP | 1 |
| Einstein, A | 1 |
| Lush, R | 1 |
| Ko, YJ | 1 |
| Henner, WD | 1 |
| Bubley, G | 1 |
| Merica, EA | 1 |
| Garg, V | 1 |
| Ette, E | 1 |
| Harding, MW | 1 |
| Dalton, WS | 1 |
| Calais, G | 1 |
| Ikeda, M | 1 |
| Okusaka, T | 1 |
| Ueno, H | 1 |
| Takezako, Y | 1 |
| Morizane, C | 1 |
| Kars, A | 1 |
| Baltali, E | 1 |
| Tekuzman, G | 1 |
| Firat, D | 1 |
| Alakavuklar, M | 1 |
| James, ND | 1 |
| Bloomfield, D | 1 |
| Luscombe, C | 1 |
| Collins, R | 1 |
| Trowman, R | 1 |
| Norman, G | 1 |
| Light, K | 1 |
| Birtle, A | 1 |
| Fenwick, E | 1 |
| Palmer, S | 1 |
| Riemsma, R | 1 |
| Martinez, V | 1 |
| Mir, O | 1 |
| Dômont, J | 1 |
| Bouscary, D | 1 |
| Goldwasser, F | 1 |
| Izumi, K | 1 |
| Kanno, H | 1 |
| Umemoto, S | 1 |
| Hasumi, H | 1 |
| Osada, Y | 1 |
| Otai, J | 1 |
| Mikata, K | 1 |
| Tsuchiya, F | 1 |
| Nagashima, Y | 1 |
| Garrett-Mayer, ES | 1 |
| Yang, YC | 1 |
| Thuret, R | 1 |
| Massard, C | 1 |
| Gross-Goupil, M | 1 |
| Escudier, B | 1 |
| Di Palma, M | 1 |
| Bossi, A | 1 |
| de Crevoisier, R | 1 |
| Chauchereau, A | 1 |
| Coley, HM | 1 |
| Yang, X | 1 |
| Cai, Y | 1 |
| Zhao, X | 1 |
| Wang, Z | 1 |
| Hong, X | 1 |
| Shen, Z | 1 |
| Ou, Z | 1 |
| Li, J | 1 |
| Hu, X | 1 |
| Moser, K | 1 |
| Pohl, A | 1 |
| Neidhart, JA | 4 |
| Gochnour, D | 2 |
| Roach, RW | 1 |
| Young, D | 2 |
| Steinberg, JA | 1 |
| McDonald, DB | 1 |
| Abu-Zahra, H | 1 |
| Yoshida, S | 1 |
| Binder, H | 1 |
| Holmes, FA | 4 |
| Yap, HY | 5 |
| Esparza, L | 4 |
| Buzdar, AU | 4 |
| Hortobagyi, GN | 5 |
| Blumenschein, GR | 4 |
| Smyth, JF | 1 |
| Cornbleet, MA | 1 |
| Stuart-Harris, RC | 1 |
| Smith, IE | 1 |
| Coleman, RE | 1 |
| Rubens, RD | 1 |
| McDonald, M | 1 |
| Mouridsen, HT | 1 |
| Rainer, H | 1 |
| van Oosterom, AT | 1 |
| DeSimone, PA | 1 |
| Gams, R | 1 |
| Bartolucci, A | 1 |
| Levin, M | 1 |
| Pandya, KJ | 1 |
| Khandekar, JD | 1 |
| Horton, J | 1 |
| Glick, JH | 1 |
| Bennett, JM | 1 |
| Muggia, FM | 1 |
| Falkson, G | 1 |
| Bodey, GP | 4 |
| Knight, WA | 1 |
| Von Hoff, DD | 1 |
| Tranum, BL | 1 |
| Fabian, C | 1 |
| Jones, SE | 2 |
| Bedikian, AY | 2 |
| Stroehlein, J | 2 |
| Korinek, J | 2 |
| Karlin, D | 2 |
| Valdivieso, M | 4 |
| Schell, FC | 2 |
| Blumenschein, G | 1 |
| Bodey, G | 1 |
| Frasci, G | 1 |
| Comella, G | 1 |
| Comella, P | 1 |
| Salzano, F | 1 |
| Cremone, L | 1 |
| Della Volpe, N | 1 |
| Imbriani, A | 1 |
| Persico, G | 1 |
| Leonardi, V | 1 |
| Meli, M | 1 |
| Palmeri, S | 1 |
| Russo, A | 1 |
| Rini, GB | 1 |
| Peralta, S | 1 |
| Rausa, L | 1 |
| Ferrero, JM | 1 |
| Pivot, X | 1 |
| Namer, M | 1 |
| Wendling, JL | 1 |
| Frenay, M | 1 |
| François, E | 1 |
| Hoch, M | 1 |
| Teissier, E | 1 |
| Hainsworth, JD | 3 |
| Patrone, F | 1 |
| Ballestrero, A | 1 |
| Ferrando, F | 1 |
| Brema, F | 1 |
| Moraglio, L | 1 |
| Valbonesi, M | 1 |
| Basta, P | 1 |
| Ghio, R | 1 |
| Gobbi, M | 1 |
| Sessarego, M | 1 |
| Vogel, CL | 2 |
| Budd, GT | 1 |
| Herzog, P | 1 |
| Bukowski, RM | 1 |
| Neijt, JP | 1 |
| Lacave, AJ | 1 |
| Splinter, TA | 1 |
| Taal, BG | 1 |
| Veenhof, CH | 1 |
| Sahmoud, T | 1 |
| Lips, CJ | 1 |
| Repetto, L | 2 |
| Miglietta, L | 2 |
| Gardin, G | 2 |
| Lanfranco, C | 1 |
| Naso, C | 1 |
| Merlini, L | 3 |
| Giudici, S | 1 |
| Venturino, A | 1 |
| Campora, E | 1 |
| Testore, F | 1 |
| Williams, SF | 1 |
| Myers, SE | 1 |
| Huffman, S | 1 |
| Mick, R | 1 |
| Bitran, JD | 1 |
| Mundt, AJ | 1 |
| Sibley, GS | 1 |
| Williams, S | 1 |
| Rubin, SJ | 1 |
| Heimann, R | 1 |
| Halpern, H | 1 |
| Weichselbaum, RR | 1 |
| Mammoliti, S | 2 |
| Caroti, C | 2 |
| Gallo, L | 2 |
| Perrone, F | 1 |
| De Placido, S | 1 |
| Carlomagno, C | 1 |
| Gravina, A | 1 |
| De Laurentiis, M | 1 |
| Del Mastro, L | 1 |
| Gridelli, C | 1 |
| Pagliarulo, C | 1 |
| Bianco, AR | 1 |
| Fields, KK | 2 |
| Elfenbein, GJ | 2 |
| Perkins, JB | 2 |
| Hiemenz, JW | 1 |
| Janssen, WE | 1 |
| Zorsky, PE | 1 |
| Ballester, OF | 1 |
| Kronish, LE | 1 |
| Foody, MC | 1 |
| Louvet, C | 1 |
| de Gramont, A | 1 |
| Demuynck, B | 1 |
| Beerblock, K | 1 |
| Varette, C | 1 |
| Soubrane, D | 1 |
| Marpeau, L | 1 |
| Pigné, A | 1 |
| Guillot, T | 1 |
| Krulik, M | 1 |
| Gomez, EG | 1 |
| Brufman, G | 1 |
| Haim, N | 1 |
| Ben-Baruch, N | 1 |
| Sulkes, A | 1 |
| Lemmens, J | 1 |
| Berteloot, P | 1 |
| Thomas, J | 1 |
| Wildiers, J | 1 |
| Paridaens, R | 1 |
| Moscinski, LC | 1 |
| Long, GD | 2 |
| Negrin, RS | 2 |
| Hoyle, CF | 1 |
| Kusnierz-Glaz, CR | 1 |
| Schriber, JR | 1 |
| Blume, KG | 2 |
| Chao, NJ | 2 |
| Subar, M | 1 |
| Muhonen, T | 1 |
| Jantunen, I | 1 |
| Pertovaara, H | 1 |
| Voutilainen, L | 1 |
| Maiche, A | 1 |
| Blomqvist, C | 1 |
| Pyrhönen, S | 1 |
| Kellokumpu-Lehtinen, P | 1 |
| Colozza, M | 1 |
| Gori, S | 1 |
| Mosconi, AM | 1 |
| Anastasi, P | 1 |
| Basurto, C | 1 |
| Ludovini, V | 1 |
| De Angelis, V | 1 |
| Giansanti, M | 1 |
| Tonato, M | 1 |
| Azim, HA | 1 |
| Fippin, LJ | 1 |
| Ernest, ML | 1 |
| Carroll, PR | 1 |
| Gisselbrecht, C | 4 |
| Extra, JM | 1 |
| Lotz, JP | 2 |
| Devaux, Y | 1 |
| Janvier, M | 2 |
| Peny, AM | 1 |
| Guillevin, L | 1 |
| Bremond, D | 1 |
| Delain, M | 1 |
| Herbrecht, R | 1 |
| Lepage, E | 1 |
| Maraninchi, D | 1 |
| Gladieff, L | 1 |
| Houyau, P | 1 |
| Mihura, J | 1 |
| Martinez, M | 1 |
| Caunes, N | 1 |
| Chevreau, C | 1 |
| Bugat, R | 1 |
| Roché, H | 2 |
| Cook, AM | 1 |
| Chambers, EJ | 1 |
| Rees, GJ | 1 |
| Panagos, GE | 1 |
| Ingle, JN | 1 |
| Kardinal, CG | 1 |
| Suman, VJ | 1 |
| Veeder, MH | 1 |
| Schaefer, PL | 1 |
| Kirschling, RJ | 1 |
| Mailliard, JA | 1 |
| Greco, FA | 2 |
| Bascioni, R | 1 |
| Giorgi, F | 1 |
| Silva, RR | 1 |
| Acito, L | 2 |
| Giustini, L | 2 |
| De Signoribus, G | 1 |
| Giuliodori, L | 1 |
| Testa, E | 1 |
| Gregory, RK | 1 |
| Powles, TJ | 1 |
| Chang, JC | 1 |
| Ashley, S | 1 |
| Martín, M | 1 |
| Casado, A | 1 |
| Llorente, L | 1 |
| López Martín, JA | 1 |
| Rodríguez Lescure, A | 1 |
| Nieto, Y | 1 |
| Ayala, F | 1 |
| Pérez Calvo, J | 1 |
| Alonso, JL | 1 |
| Pérez López, C | 1 |
| Villegas, A | 1 |
| Díaz-Rubio, E | 1 |
| Pusztai, L | 1 |
| Fraschini, G | 1 |
| Kouroussis, C | 1 |
| Androulakis, N | 1 |
| Kakolyris, S | 2 |
| Souglakos, J | 1 |
| Kotsakis, T | 1 |
| Mavroudis, D | 1 |
| Katsogridakis, K | 1 |
| Vardakis, N | 1 |
| Hatzidaki, D | 1 |
| Samonis, G | 2 |
| Vlachonikolis, J | 1 |
| Georgoulias, V | 2 |
| Curé, H | 1 |
| Morvan, F | 1 |
| Legros, M | 1 |
| Asselain, B | 1 |
| Guillemot, M | 1 |
| Mohr, M | 1 |
| Hilgenfeld, E | 1 |
| Fietz, T | 1 |
| Hoppe, B | 1 |
| Koenigsmann, M | 1 |
| Hoffmann, M | 1 |
| Knauf, WU | 1 |
| Cassens, U | 1 |
| Sibrowski, W | 1 |
| Kienast, J | 1 |
| Thiel, E | 1 |
| Berdel, WE | 1 |
| Koukourakis, M | 1 |
| Vlachonicolis, J | 1 |
| Kalbakis, K | 1 |
| Agelaki, S | 1 |
| Chalkiadakis, G | 1 |
| Sanidas, E | 1 |
| Tsiftsis, D | 1 |
| Costanzo, FD | 1 |
| Sdrobolini, A | 1 |
| Manzione, L | 1 |
| Bilancia, D | 1 |
| Gasperoni, S | 1 |
| Valenti, L | 1 |
| Fioriti, L | 1 |
| Angiona, S | 1 |
| Cristofanilli, M | 1 |
| Valero, V | 1 |
| Conaway, M | 1 |
| Picus, J | 1 |
| Kirshner, J | 1 |
| Hars, V | 1 |
| Trump, D | 1 |
| Winer, EP | 1 |
| Vogelzang, NJ | 1 |
| Hu, WW | 1 |
| Stockerl-Goldstein, KE | 1 |
| Johnston, LJ | 1 |
| Smith, MR | 1 |
| Wang, J | 1 |
| Halford, S | 1 |
| Rigg, A | 1 |
| Roylance, R | 1 |
| Lynch, M | 1 |
| Waxman, J | 1 |
| Culine, S | 2 |
| Droz, JP | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Harvey, J | 1 |
| Cantrell, J | 1 |
| Campbell, M | 1 |
| Cartmell, A | 1 |
| Urba, W | 1 |
| Modiano, M | 1 |
| Schuster, M | 1 |
| Rubin, A | 1 |
| Newcomb, T | 1 |
| Ghalie, R | 1 |
| Gazet, JC | 1 |
| Ford, HT | 1 |
| Gray, R | 1 |
| McConkey, C | 1 |
| Sutcliffe, R | 1 |
| Quilliam, J | 1 |
| Makinde, V | 1 |
| Lowndes, S | 1 |
| Coombes, RC | 1 |
| Tan, SM | 1 |
| Cheung, KL | 1 |
| Willsher, PC | 1 |
| Blamey, RW | 1 |
| Chan, SY | 1 |
| Robertson, JF | 1 |
| Colomer, R | 1 |
| Esteban, E | 1 |
| Barceló, R | 1 |
| Benavides, M | 1 |
| Puertas, J | 1 |
| Arcediano, A | 1 |
| Tornamira, MV | 1 |
| Valentín, V | 1 |
| Muñoz, A | 1 |
| Cortés-Funes, H | 1 |
| Hornedo, J | 1 |
| Gleave, ME | 1 |
| Klasa, R | 1 |
| Murray, N | 1 |
| Bryce, C | 1 |
| Lopes de Menezes, DE | 1 |
| D'Aloisio, S | 1 |
| Tolcher, AW | 1 |
| Khalaf, A | 1 |
| Pfister, C | 1 |
| Hellot, MF | 1 |
| Dunet, F | 1 |
| Moussu, J | 1 |
| Grise, P | 1 |
| Degardin, M | 1 |
| Hecquet, B | 1 |
| Bonneterre, J | 1 |
| Adenis, A | 1 |
| Pion, JM | 1 |
| Demaille, A | 1 |
| Gupta, P | 1 |
| Tandon, R | 1 |
| Hidalgo, OF | 1 |
| Gonzalez, FG | 1 |
| Vieitez, JM | 1 |
| Rebollo, J | 1 |
| Tangco, E | 1 |
| Herranz, P | 1 |
| Pfeiffer, P | 1 |
| Cold, S | 1 |
| Rose, C | 1 |
| Hu, OY | 1 |
| Chang, SP | 1 |
| Law, CK | 1 |
| Jian, JM | 1 |
| Chen, KY | 1 |
| Schaudig, K | 1 |
| Thomssen, C | 1 |
| Jänicke, F | 1 |
| Graeff, H | 1 |
| Barni, S | 1 |
| Lissoni, P | 1 |
| Paolorossi, F | 1 |
| Rescaldani, R | 1 |
| Crispino, S | 1 |
| Archili, C | 1 |
| Cattaneo, G | 1 |
| Tancini, G | 1 |
| Borovik, R | 1 |
| Robinson, E | 1 |
| Mennel, RG | 1 |
| Brooks, B | 1 |
| Westrick, MA | 1 |
| Allison, MA | 1 |
| Paulson, RS | 1 |
| Tilmann, K | 1 |
| Rea, B | 1 |
| Andrews, MB | 1 |
| Johnson, DH | 1 |
| Queirolo, P | 1 |
| Guido, T | 1 |
| Pronzato, P | 1 |
| Rosso, R | 1 |
| Wallerstein, R | 1 |
| Spitzer, G | 1 |
| Dunphy, F | 1 |
| Huan, S | 1 |
| Hortobagyi, G | 1 |
| Yau, J | 1 |
| Buzdar, A | 1 |
| Holmes, F | 1 |
| Theriault, R | 1 |
| Ewer, M | 1 |
| Thürlimann, B | 1 |
| Senn, HJ | 1 |
| Jungi, WF | 1 |
| Burghouts, JT | 1 |
| Bishop, JF | 1 |
| Raghavan, D | 1 |
| Woods, R | 1 |
| Coates, A | 1 |
| Burns, I | 1 |
| Jeal, PN | 1 |
| Hillcoat, BL | 1 |
| Tattersall, MN | 1 |
| Henderson, IC | 1 |
| Allegra, JC | 1 |
| Woodcock, T | 1 |
| Wolff, S | 1 |
| Bryan, S | 1 |
| Cartwright, K | 1 |
| Dukart, G | 1 |
| Henry, D | 1 |
| Runge, HM | 1 |
| Meerpohl, HG | 1 |
| Pfleiderer, A | 1 |
| Hausmaninger, H | 3 |
| Lehnert, M | 2 |
| Steger, G | 1 |
| Sevelda, P | 1 |
| Michlmayr, G | 1 |
| Hehenwarter, W | 1 |
| Fridrik, M | 1 |
| Samonigg, H | 1 |
| Schiller, L | 1 |
| Manfreda, D | 1 |
| Schlumberger, M | 1 |
| Parmentier, C | 1 |
| Belpomme, D | 2 |
| Cour, V | 2 |
| Le Rol, A | 2 |
| Mignot, L | 1 |
| Marty, M | 2 |
| Godeffroy, W | 1 |
| Maral, J | 2 |
| Shpall, EJ | 1 |
| Jones, RB | 1 |
| Holland, JF | 1 |
| Bhardwaj, S | 1 |
| Paciucci, PA | 1 |
| Wilfinger, CL | 1 |
| Strashun, A | 1 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengecti, S | 1 |
| Berkarda, B | 1 |
| Roach, R | 1 |
| Hoth, D | 1 |
| Gams, RA | 1 |
| Nelson, O | 1 |
| Birch, R | 1 |
| Hug, V | 1 |
| Heritier, F | 1 |
| Michaud, G | 1 |
| George, C | 1 |
| Bezwoda, WR | 1 |
| Hesdorffer, CS | 1 |
| Dansey, RD | 1 |
| Nathanson, L | 1 |
| Williams, ME | 1 |
| Ogawa, M | 1 |
| Kubo, K | 1 |
| Tominaga, T | 1 |
| Nomura, Y | 1 |
| Ota, K | 1 |
| Yoshida, M | 1 |
| Taguchi, T | 1 |
| Hoshino, A | 1 |
| Wilson, KS | 1 |
| Paterson, AH | 1 |
| Muss, HB | 1 |
| Bundy, BN | 1 |
| DiSaia, PJ | 1 |
| Ehrlich, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated [NCT00417079] | Phase 3 | 755 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer (HRPC) Patients Previously Treated With Chemotherapy[NCT00331344] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis[NCT03114254] | Phase 2 | 17 participants (Actual) | Interventional | 2014-12-05 | Completed | ||
| A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)[NCT01578655] | Phase 3 | 630 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Title: A Pilot Study Evaluating the Safety and Feasibility of Custirsen (OGX-011) in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer[NCT00327340] | Phase 2 | 70 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone[NCT03261336] | Phase 2 | 1 participants (Actual) | Interventional | 2017-01-06 | Terminated (stopped due to can not meet enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause.~In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 12.7 |
| Cabazitaxel + Prednisone | 15.1 |
"Tumor Overall Response Rate (ORR) (only in patients with measurable disease):~Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria.~Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD.~Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 4.4 |
| Cabazitaxel + Prednisone | 14.4 |
Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 7.7 |
| Cabazitaxel + Prednisone | 9.2 |
PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 17.8 |
| Cabazitaxel + Prednisone | 39.2 |
"Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score & noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy.~Evaluation of the PPI & analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)" (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | NA |
| Cabazitaxel + Prednisone | 11.1 |
Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 1.4 |
| Cabazitaxel + Prednisone | 2.8 |
"In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later.~In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later." (NCT00417079)
Timeframe: at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 3.1 |
| Cabazitaxel + Prednisone | 6.4 |
Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST) (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 5.4 |
| Cabazitaxel + Prednisone | 8.8 |
Cohorts of 3 patients will be enrolled at each dose level; if 1 dose limiting toxicity (DLT) is observed then the cohort will be expanded to 6 patients. If a second DLT is observed, the previous dose level will be considered the maximum tolerated dose (MTD). If all observed DLT are due to neuropathy (specific to ixabepilone), then we would consider the previous dose level of Ixabepilone the MTD for that drug, and escalate mitoxantrone hydrochloride as described above to a maximum dose of 12 mg/m^2. Toxicities will be tabulated by grade for each dose cohort and overall for all patients accrued to the phase I study. (NCT00331344)
Timeframe: Course 1 (first 21 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I Group I | 0 |
| Phase Group II | 0 |
| Phase I Group III | 0 |
| Phase I Group IV | 1 |
| Phase I Group V | 2 |
| Phase I Group VI | 2 |
| Phase I Group Va | 0 |
| Phase I Group VIa | 1 |
"Descriptive statistics will be calculated to characterize the disease and treatment factors including the proportion responding with a 95% confidence interval. If accrual is completed and more than 15 of 58 patients show > 50% Prostate Specific Antigen (PSA) declines after 3 courses, then the null hypothesis of a 20% response proportion will be rejected. PSA declines for individual patients will be plotted in the form of a waterfall diagram of maximal PSA declines.~58 patients were enrolled for phase II, two were ineligible so 56 patients were analyzed." (NCT00331344)
Timeframe: Every 3 courses until cancer progression/excessive toxicity or death
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Combination Chemotherapy) | 25 |
This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 for adverse event monitoring and reporting. The cumulative grade 3 or higher adverse events for all dose levels are noted below and in the table of adverse events. (NCT00331344)
Timeframe: Every 21 days until cancer progression/excessive toxicity or death
| Intervention | Adverse Events (above threshold) (Number) |
|---|---|
| Phase I Treatment (Groups I-VIa) | 62 |
Measured from the start of protocol therapy until RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.0 progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00331344)
Timeframe: Every 3 months until cancer progression/excessive toxicity or death
| Intervention | months (Median) |
|---|---|
| Treatment (Combination Chemotherapy) | 4.4 |
PSA or prostate specific antigen is a marker for prostate cancer. A PSA response was defined as a decrease in PSA values of ≥ 50% relative to baseline on two or more consecutive measurements that were 4-6 weeks apart. (NCT00327340)
Timeframe: PSA was evaluated at screening, on Day 1 of each cycle, at the end of treatment visit and during off-treatment follow up (up to 27 months)
| Intervention | percentage of participants (Number) |
|---|---|
| OGX-011 / Mitoxantrone/Prednisone | 17 |
| OGX-011 / Docetaxel/Prednisone | 31 |
Time to pain progression was defined as the time (months) from the first dose of OGX-011 to the first documentation of pain or analgesic progression or initiation of palliative radiation therapy. Pain response was defined as either a decrease of at least two points on the 11-point Worst Pain Scale, without an increase in analgesic level, maintained for at least two consecutive measurements approximately three weeks apart -or- a decrease in analgesic level, without an increase in pain score, maintained for at least two consecutive measurements approximately three weeks apart. (NCT00327340)
Timeframe: Enrollment until pain progression (up to 21 months)
| Intervention | months (Number) |
|---|---|
| OGX-011 + Mitoxantrone + Prednisone | 5.2 |
| OGX-011 + Docetaxel + Prednisone | 7.2 |
Serum clusterin samples were collected prior to receiving OGX-011 loading dose 1, prior to study treatment on Day 1 of each cycle, and at the end of treatment. PSA was evaluated at screening, on Day 1 of each cycle, at the end of treatment visit, and during off-treatment follow-up. PSA response was defined in the protocol as a decrease in PSA of ≥ 50% relative to baseline on two or more consecutive measurements 4-6 weeks apart. (NCT00327340)
Timeframe: Enrollment until disease progression (up to 13 months)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Minimum clusterin level < or = to 45 mcg/mL | Minimum clusterin level > 45 mcg/mL | |
| OGX-011 + Docetaxel + Prednisone | 24 | 7 |
| OGX-011 + Mitoxantrone + Prednisone | 22 | 4 |
"Safety and tolerability were based on Adverse Events (AE) and Serious Adverse Events (SAE) graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE).~The CTCAE has 5 grades with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1=Mild AE; Grade 2=Moderate AE; Grade 3=Severe AE; Grade 4=Life-threatening or disabling AE; and Grade 5=Death related to AE." (NCT00327340)
Timeframe: Subjects were followed for safety from enrollment for up to 8 months (9 three-week cycles plus 30 days after end of treatment)
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Percent of Subjects with Serious Adverse Events | Percent of Subjects with Grade 5 Adverse Events | Percent of Subjects with Grade 4 Adverse Events | Percent of Subjects with Grade 3 Adverse Events | Percent of Subjects with Grade 2 Adverse Events | Percent of Subjects with Grade 1 Adverse Events | Percent of Subjects who Discontinued Study Drug | |
| OGX-011 + Docetaxel + Prednisone | 26 | 4 | 15 | 52 | 98 | 100 | 17 |
| OGX-011 + Mitoxantrone + Prednisone | 26 | 13 | 26 | 70 | 83 | 100 | 22 |
Descriptive analysis of observed toxicity and patient reports of tolerating experimental treatment (NCT03261336)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Calcitriol, Ketoconazole, Hydrocortisone | 1 |
17 reviews available for mitoxantrone and Neoplasm Metastasis
| Article | Year |
|---|---|
Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
Topics: Aged; Antineoplastic Agents; Bias; Cost-Benefit Analysis; Humans; Male; Middle Aged; Mitoxantrone; N | 2018 |
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Clinical Trials, Phase III as Topic; D | 2019 |
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlo | 2013 |
Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Epothilones; Huma | 2008 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cl | 2011 |
Chemotherapy for prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clin | 2002 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2006 |
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Res | 2006 |
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer.
Topics: Breast Neoplasms; Carrier Proteins; DNA Repair; Drug Delivery Systems; Drug Resistance, Multiple; Dr | 2008 |
[Recent developments in chemotherapy of malignant diseases].
Topics: Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1982 |
Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; | 1995 |
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cycl | 1995 |
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2000 |
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1992 |
Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 1992 |
Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma.
Topics: Adult; Chromatography, High Pressure Liquid; Female; Humans; Male; Metabolic Clearance Rate; Middle | 1992 |
80 trials available for mitoxantrone and Neoplasm Metastasis
| Article | Year |
|---|---|
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2019 |
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Mi | 2013 |
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epothilones; Hum | 2011 |
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Drug Resistance, | 2013 |
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Eto | 2015 |
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Granulocyte Colony | 2016 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; | 2008 |
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplas | 2010 |
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Estr | 2010 |
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Cell Line, Tumor; Disease-Free Survival; | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Pr | 2012 |
[Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxant | 2012 |
A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel | 2002 |
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug | 2003 |
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2003 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2005 |
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Kinetics; Mal | 2007 |
Biweekly docetaxel-containing chemotherapy may be the optimal schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Admin | 2008 |
A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer.
Topics: Adult; Aged; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Heart; | 1984 |
Mitoxantrone and cyclophosphamide in advanced breast cancer: a pilot study.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1984 |
Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1984 |
Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1995 |
A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dos | 1995 |
[Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1995 |
The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1993 |
Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modal | 1995 |
Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; | 1994 |
Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group.
Topics: Adenoma, Islet Cell; Adult; Aged; Alkaline Phosphatase; Apudoma; Carcinoid Tumor; Carcinoma, Medulla | 1995 |
Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedul | 1994 |
Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1994 |
Mitoxantrone, 5-fluorouracil and levo-leucovorin as salvage treatment in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1994 |
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1994 |
Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1993 |
Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1993 |
A phase I clinical trial of a combination of mitoxantrone, 5-fluorouracil, and high-dose leucovorin given on a day 1 and day 8 schedule to patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1994 |
Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Ne | 1993 |
Mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fe | 1995 |
Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Filgrastim; G | 1996 |
Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1996 |
Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients.
Topics: Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluoroura | 1996 |
Treatment of metastatic breast cancer by navelbine, mitoxantrone and continuous infusion 5-fluorouracil (FMN regimen): results of a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1996 |
A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Tra | 1996 |
Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1996 |
[A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 1996 |
Comparison of mitozantrone and epirubicin in advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Epirubicin; Heart Diseases; Humans; Middle Aged; Mitoxantro | 1996 |
Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; | 1997 |
Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1997 |
Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Fema | 1997 |
Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1997 |
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 1997 |
Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, | 1999 |
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Respo | 1999 |
[Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1999 |
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combi | 1999 |
First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 1999 |
Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 1999 |
Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Topics: Adult; Algorithms; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; | 1999 |
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Therapy, Combination; Humans; Hydrocorti | 1999 |
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Feasibility Studies; Female | 1999 |
Adjuvant mitozantrone chemotherapy in advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem | 2000 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2001 |
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 2001 |
Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2001 |
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; G | 2001 |
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2001 |
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1992 |
Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Eva | 1992 |
[Mitoxantrone monotherapy in metastatic breast cancer--initial results of a prospective randomized study in "low risk" patients].
Topics: Breast Neoplasms; Drug Administration Schedule; Female; Humans; Mitoxantrone; Neoplasm Metastasis; P | 1991 |
Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1991 |
Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1991 |
Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
Topics: Adenocarcinoma; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Female; He | 1989 |
Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; G | 1989 |
Intensive single-agent mitoxantrone for metastatic breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Humans; Leukopenia; Mitoxantrone; N | 1988 |
Vindesine-mitoxantrone (VM) versus vindesine-4'-epidoxorubicin (VE) in metastatic breast cancer: a prospective randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration S | 1988 |
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini | 1987 |
A comparison of mitoxantrone and doxorubicin in breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Dose | 1986 |
Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.
Topics: Adult; Anthraquinones; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug | 1986 |
48 other studies available for mitoxantrone and Neoplasm Metastasis
| Article | Year |
|---|---|
Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Aspirin; Car | 2016 |
A Nanoplatform to Amplify Apoptosis-to-Pyroptosis Immunotherapy via Immunomodulation of Myeloid-Derived Suppressor Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female; | 2021 |
In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Computer Simulation; Down-Regulation; D | 2018 |
Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; CD8-Positive T | 2019 |
Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Mitoxantrone; Neoplas | 2013 |
A Successfully Treated Metastatic Choriocarcinoma Coexistent With Pregnancy: A Case Report of a 4-Year Follow-Up.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Choriocarcinoma; Cyclophosp | 2016 |
Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Anxiety; Area Under | 2010 |
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Dose-Respons | 2011 |
[Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antine | 2005 |
Tamoxifen versus tamoxifen + mitoxantrone treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Controlled Clinical T | 1989 |
Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.
Topics: Androgens; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Humans; In Situ Hybri | 2007 |
[A case of recurrent renal cell carcinoma which recurred after fourth surgical resection and survived for about 2 years by medroxyporgesterone acetate administration].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 2007 |
The postchemotherapy PSA surge syndrome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineo | 2008 |
Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study.
Topics: Adult; Aged; Anthraquinones; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Injecti | 1984 |
Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma.
Topics: Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Humans; Mitoxantrone; Neo | 1984 |
Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Human | 1984 |
Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1983 |
Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Drug Evaluation; | 1983 |
Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Colonic Neoplasms; Drug Evaluation; | 1983 |
Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukocyte Count | 1983 |
Potential cardiotoxicity with mitoxantrone.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Heart | 1982 |
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Agranulocytosis; Anthracenes; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Dru | 1981 |
Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, | 1993 |
Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Cyclopho | 1995 |
Risk stratification for high-dose chemotherapy in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Humans; | 1996 |
[High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami | 1997 |
Successful treatment with mitoxantrone chemotherapy of acute disseminated intravascular coagulation due to metastatic androgen independent prostate cancer.
Topics: Acute Disease; Aged; Aged, 80 and over; Androgens; Disseminated Intravascular Coagulation; Humans; M | 2000 |
[Value of mitoxantrone in metastatic hormone-resistant prostate cancer].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Drug Resistance, Neoplasm; Hum | 2002 |
[Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Mitoxantrone; N | 2002 |
Mitoxantrone for advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Resp | 1992 |
Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; T-Lym | 1991 |
Mitoxantrone as second-line single agent in metastatic breast cancer.
Topics: Breast Neoplasms; Female; Heart; Heart Function Tests; Humans; Infusions, Intravenous; Menopause; Mi | 1991 |
Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Femal | 1991 |
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brea | 1990 |
Anthracycline-carboplatin combination in metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Fem | 1990 |
Mitoxantrone, methotrexate and chlorambucil in metastatic breast cancer, a combination with relatively low subjective toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 1990 |
Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Heart Diseases; Hematologic Diseas | 1987 |
Mitoxantrone therapy of advanced adenocarcinoma of the endometrium. A phase II trial.
Topics: Adenocarcinoma; Aged; Drug Evaluation; Female; Follow-Up Studies; Humans; Middle Aged; Mitoxantrone; | 1989 |
Phase II evaluation of mitoxantrone in advanced non anaplastic thyroid cancer.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; | 1989 |
[Prolonged remissions induced by the combination vindesine, mitoxantrone, mitomycine C in metastatic breast cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1987 |
Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Flu | 1987 |
Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema | 1987 |
Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administrat | 1987 |
Mitoxantrone salvage in heavily pretreated advanced breast cancer.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Combined Modality Therapy; Drug Resistance; Female; Human | 1987 |
[Phase II study of mitoxantrone in advanced breast cancer].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; | 1986 |
First-line mitoxantrone chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1986 |
Mitoxantrone for carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Uterin | 1987 |
[Mitoxantrone in a combination regimen in advanced breast cancer].
Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1985 |